PDS Biotech Presents Promising VERSATILE-002 Data for HPV16-Positive Head and Neck Cancer
核心洞察
PDS Biotech will present updated data from the VERSATILE-002 trial at the ESMO Congress 2024 in Barcelona, Spain.
The trial evaluates Versamune® HPV (PDS0101) in combination with KEYTRUDA® (pembrolizumab) as a first-line treatment.
The treatment targets patients with HPV16-positive recurrent/metastatic head and neck squamous cell carcinoma (搜索) (HNSCC).
PDS Biotechnology Corporation (搜索) is set to present updated data from its VERSATILE-002 trial at the European Society for Medical Oncology (ESMO) Congress 2024, highlighting a potential new treatment approach for HPV16-positive recurrent/metastatic head and neck squamous cell carcinoma (搜索) (HNSCC). The poster presentation will take place on September 14, 2024, in Barcelona, Spain.
The VERSATILE-002 trial investigates the efficacy of Versamune® HPV (formerly PDS0101) in combination with KEYTRUDA® (pembrolizumab) as a first-line treatment for patients with HPV16 (搜索)-positive HNSCC. This combination aims to leverage the targeted immunotherapy of Versamune® HPV with the immune checkpoint inhibition of pembrolizumab to improve patient outcomes.
Trial Details and Presentation
The presentation, poster number 879P, is titled "VERSATILE-002: Survival with First-Line Treatment with PDS0101 Therapeutic Vaccine and Pembrolizumab in HPV16-positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (搜索) (HNSCC)." It will be presented by Jared Weiss, M.D., Section Chief of Thoracic and Head/Neck Oncology, Professor of Medicine at University of North Carolina, and Principal Investigator of the VERSATILE-002 clinical trial.
Following the presentation, the poster will be accessible in the Investor Relations section of PDS Biotech’s website.
About Versamune® HPV
Versamune® HPV is PDS Biotech’s lead investigational targeted immunotherapy. It is being developed not only in combination with standard-of-care immune checkpoint inhibitors like pembrolizumab but also in a triple combination that includes PDS01ADC (搜索), an IL-12 fused antibody-drug conjugate (ADC), further enhancing its potential to combat HPV16 (搜索)-positive cancers.
PDS Biotech is focusing on transforming how the immune system targets and eradicates cancers, as well as developing innovative infectious disease vaccines. The company plans to initiate a pivotal clinical trial in 2024 to further advance its lead program in advanced HPV16 (搜索)-positive head and neck squamous cell cancers.